An antisense circular RNA circSCRIB enhances cancer progression by suppressing parental gene splicing and translation.


Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
01 09 2021
Historique:
received: 19 04 2021
revised: 29 06 2021
accepted: 31 07 2021
pubmed: 9 8 2021
medline: 9 2 2022
entrez: 8 8 2021
Statut: ppublish

Résumé

Circular RNAs (circRNAs) represent a large group of non-coding RNAs that are widely detected in mammalian cells. Although most circRNAs are generated in a sense orientation, there is a group of circRNAs that are synthesized in an antisense orientation. High-throughput analysis of breast cancer specimens revealed a significant enrichment of 209 antisense circRNAs. The tumor suppressor SCRIB was shown to potentially produce thirteen circRNAs, three of which are in an antisense orientation. Among these three circRNAs, circSCRIB (hsa_circ_0001831) was the most enriched in the breast cancer panel. This antisense SCRIB circRNA was shown to span one intron and two exons. We hypothesized that this circRNA could decrease pre-mRNA splicing and mRNA translation. To test this, we generated a hsa_circ_0001831 expression construct. We found that there was decreased SCRIB mRNA production but increased cancer cell proliferation, migration, and invasion. In comparison, an exonic sequence construct did not affect mRNA splicing but decreased protein translation, leading to increased E-cadherin expression and decreased expression of N-cadherin and vimentin. Thus, there was increased cell migration, invasion, proliferation, colony formation, and tumorigenesis. Our study suggests a novel modulatory role of antisense circRNAs on their parental transcripts. This may represent a promising approach for developing circRNA-directed therapy.

Identifiants

pubmed: 34365033
pii: S1525-0016(21)00396-8
doi: 10.1016/j.ymthe.2021.08.002
pmc: PMC8417507
pii:
doi:

Substances chimiques

Membrane Proteins 0
RNA, Antisense 0
RNA, Circular 0
SCRIB protein, human 0
Tumor Suppressor Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2754-2768

Subventions

Organisme : CIHR
ID : PJT-153105
Pays : Canada
Organisme : CIHR
ID : PJT-155962
Pays : Canada
Organisme : CIHR
ID : PJT-166107
Pays : Canada

Informations de copyright

Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

Nat Commun. 2014;5:2914
pubmed: 24394498
Cell Death Differ. 2019 Dec;26(12):2758-2773
pubmed: 31092884
PLoS One. 2012;7(3):e34329
pubmed: 22461910
BMC Cancer. 2010 Mar 22;10:108
pubmed: 20307320
Nucleic Acids Res. 2013 Nov;41(21):9688-704
pubmed: 23990326
Mol Ther. 2021 May 5;29(5):1683-1702
pubmed: 33484969
Mol Cancer. 2015 Sep 17;14:169
pubmed: 26376988
Mol Ther. 2020 Mar 4;28(3):929-945
pubmed: 32017889
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747
Oncogene. 2016 Jul 28;35(30):3919-31
pubmed: 26657152
Mol Ther Nucleic Acids. 2020 Sep 4;21:568-576
pubmed: 32721877
Mol Ther. 2019 Sep 4;27(9):1638-1652
pubmed: 31153828
Nat Cell Biol. 2016 Nov;18(11):1244-1252
pubmed: 27694890
Cell Cycle. 2017;16(22):2204-2211
pubmed: 28727484
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
Semin Cancer Biol. 2020 Oct 6;:
pubmed: 33035655
Circ Res. 2021 Aug 20;129(5):568-582
pubmed: 34261347
Am J Pathol. 2011 Jun;178(6):2478-83
pubmed: 21549346
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Mol Ther. 2020 Mar 4;28(3):914-928
pubmed: 31951832
Nucleic Acids Res. 2016 Feb 18;44(3):1370-83
pubmed: 26657629
Circ Res. 2020 Jul 31;127(4):e108-e125
pubmed: 32392088
Mol Ther. 2020 Jun 3;28(6):1506-1517
pubmed: 32304667
Oncogene. 2007 Apr 5;26(16):2272-82
pubmed: 17043654
Cell Death Differ. 2011 Sep;18(9):1470-7
pubmed: 21617693
Cell Death Differ. 2019 Jul;26(7):1299-1315
pubmed: 30349076
J Cell Biol. 2019 Mar 4;218(3):742-756
pubmed: 30598480
Mol Cell. 2013 Dec 12;52(5):679-92
pubmed: 24211266
PLoS Genet. 2013;9(9):e1003777
pubmed: 24039610
Mol Ther. 2021 Mar 3;29(3):1138-1150
pubmed: 33279723
Nucleic Acids Res. 2016 Apr 7;44(6):2846-58
pubmed: 26861625
Trends Genet. 2017 Aug;33(8):540-552
pubmed: 28629949
Cell. 2019 Feb 7;176(4):831-843.e22
pubmed: 30735634
Cell Death Dis. 2019 May 1;10(5):362
pubmed: 31043588
Mol Cancer. 2019 May 22;18(1):98
pubmed: 31118036
Cell Death Differ. 2018 Dec;25(12):2195-2208
pubmed: 29795334
Mol Cancer. 2010 Sep 21;9:251
pubmed: 20858260
Science. 2014 Apr 18;344(6181):310-3
pubmed: 24744378
Int J Mol Sci. 2018 Jun 25;19(7):
pubmed: 29941860
J Clin Invest. 2011 Nov;121(11):4257-67
pubmed: 21965329
Cell Death Differ. 2017 Sep;24(9):1609-1620
pubmed: 28622299
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Cell Cycle. 2018;17(23):2644-2654
pubmed: 30488762
Proc Natl Acad Sci U S A. 2020 Jun 16;117(24):13188-13190
pubmed: 32471949
Oncogene. 2019 Jul;38(28):5750
pubmed: 31197212
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Circ Res. 2018 Jan 19;122(2):246-254
pubmed: 29133306
Mol Ther. 2019 Aug 7;27(8):1350-1363
pubmed: 31324392
Signal Transduct Target Ther. 2021 May 21;6(1):185
pubmed: 34016945
Mol Cancer. 2018 Nov 19;17(1):160
pubmed: 30454010
Development. 2019 Nov 21;146(22):
pubmed: 31628110
Mol Ther. 2020 May 6;28(5):1287-1298
pubmed: 32229309
Circulation. 2020 Aug 11;142(6):556-574
pubmed: 32441115
Oncogene. 2012 Aug 9;31(32):3696-708
pubmed: 22179838
Oncogene. 2018 Nov;37(44):5829-5842
pubmed: 29973691
Bioessays. 2003 Jun;25(6):542-53
pubmed: 12766944
RNA Biol. 2019 Jul;16(7):899-905
pubmed: 31023147
Nat Biotechnol. 2014 May;32(5):453-61
pubmed: 24811520
Cancer Lett. 2018 Jul 28;427:18-27
pubmed: 29653267
Blood. 2018 Nov 29;132(22):2375-2388
pubmed: 30181176
Cancer Lett. 2019 Sep 10;459:216-226
pubmed: 31199987
J Cell Biochem. 2014 Oct;115(10):1829-39
pubmed: 24906090
Aging (Albany NY). 2019 Dec 9;11(23):11369-11381
pubmed: 31819016
Mol Cell. 2013 Sep 26;51(6):792-806
pubmed: 24035497

Auteurs

Jian Ma (J)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

William W Du (WW)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Kaixuan Zeng (K)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Nan Wu (N)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Ling Fang (L)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; China-Japan Union Hospital of Jilin University, Jilin, China.

Juanjuan Lyu (J)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Albert J Yee (AJ)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.

Burton B Yang (BB)

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada. Electronic address: byang@sri.utoronto.ca.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH